Skip to main content

Advertisement

Table 2 Uni- and multivariate analysis in locally advanced rectal adenocarcinoma patients

From: Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study

  Univariate Multivariate
Variable OR (95 % CI) p value OR (95 % CI) p value
Age (continuous) 1.03 (0.99–1.10) 0.145   
Gender (categorical)   0.544   
 Male Reference    
 Female 0.72 (0.25–2.10)    
ECOG performance status (categorical)     
 0 Reference 0.802   
  ≥ 1 0.87 (0.31–2.40)    
Tumor invasion depth (categorical)     
 T1-T2 Reference 0.836   
 T3-T4 0.85 (0.20 – 3.70)    
Lymph node metastases (categorical)     
 N0 Reference 0.152   
 N+ 0.31 (0.06 – 1.54)    
Grade of differentiation (categorical)     
 Low grade Reference 0.465   
 Moderate-High grade 0.64 (0.19–2.13)    
LVI (categorical)     
 No Reference 0.108   
 Yes 0.23 (0.04–1.38)    
Neoadjuvant chemoradiotherapy (categorical)     
 RDT- Flouropyrimidines Reference 0.260   
 RDT- Flouropyrimidines - Oxaliplatin 0.49 (0.14–1.70)    
Tumor size (continuous) 0.65 (0.46–0.90) 0.011 0.65 (0.45–0.94) 0.021
Anal verge distance (continuous) 0.96 (0.82–1.12) 0.610   
VRK1 HSCORE (continuous) 1.20 (1.01–1.43) 0.033   
VRK2 HSCORE (continuous) 1.23 (1.03–1.50) 0.023   
COMPOSITE SCORE (continuous) 1.24 (1.07–1.44) 0.004 1.24 (1.07–1.48) 0.005
  1. Abbreviations: OR odds ratio, CI confidence interval, LVI lymphovascular invasion, ECOG Eastern cooperative oncology; group, RDT radiotherapy
  2. β0 = 1.57/βtumor size = -0.44/βComposite score = 0.22